

## CD40L inhibits cell growth of THP-1 cells by suppressing the PI3K/Akt pathway [Corrigendum]

Feng Z, Chen Q, Ren M, Tian Z, Gong Y. *OncoTargets Ther.* 2019;12:3011–3017.

The author list and affiliations should be:

Zhongxin Feng,<sup>1</sup> Qi Chen,<sup>1</sup> Mingqiang Ren,<sup>1</sup> Zuguo Tian,<sup>1</sup> Yuping Gong<sup>2</sup>

<sup>1</sup>Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China;  
<sup>2</sup>Department of Hematology, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China

The corresponding author should be:

Correspondence: Qi Chen  
Department of Hematology, Affiliated Hospital of Zunyi Medical University, No149, Dalian Road, Guizhou, Zunyi 563003, People's Republic of China  
Tel +86 851 2860 8538  
Fax +86 851 2860 8538  
Email [zyfychenqi@163.com](mailto:zyfychenqi@163.com)

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>